Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine

DGAP-News: Dermapharm Holding SE

/ Key word(s): Alliance

10.09.2020 / 14:53

The issuer is solely responsible for the content of this announcement.

Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine

Grünwald, September 10, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas, will support the vaccine developer BioNTech SE in part of the vaccine production of BNT162b2 starting in the fourth quarter of 2020. Once approval for the vaccine has been received, the Dermapharm Group will make production capacities available and expand them at its German site in order to offer BioNTech the greatest possible support.

Together with the collaboration partner Pfizer, BioNTech has initiated a global Phase 2b/3 study involving the COVID-19 vaccine BNT162b2. Provided the study is successful, BioNTech and Pfizer plan to submit an application for marketing authorisation or regulatory approval from October 2020.

If the COVID-19 vaccine candidate BNT162b2 is approved, BioNTech and Pfizer plan to provide up to 100 million vaccine doses worldwide by the end of this year and up to 1.3 billion doses next year. For this purpose, the Dermapharm Group will make production capacities available immediately and expand them as quickly as possible. The active ingredient, the mRNA, is manufactured in Germany by BioNTech.

“Dermapharm has unique know-how in the manufacture of aseptic products and in the handling of lipids, to which a key function is attributed in the formulation of vaccines,” commented Dr. Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE.

Dermapharm has created the necessary conditions in its production facility in a very short time.

“This would have been unthinkable without the constructive cooperation with BioNTech, our suppliers, employees and the responsible authorities. We are very proud and highly motivated to be able to help fight the pandemic. The cooperation with BioNTech also underscores the importance of maintaining production capacities for pharmaceuticals in Germany / Europe.”

 

Company profile:

Dermapharm – Pharmaceutical Excellence “Made in Germany”

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a trained medical and pharmaceutical sales force. Dermapharm has more than 380 active pharmaceutical ingredients for more than 1,300 marketing authorisations (Arzneimittelzulassungen), which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This range makes the company unique. Besides Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business that operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2019. In the “Herbal extracts” segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.

With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.

Contacts

Investor Relations
& Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
E-mail: ir@dermapharm.com
cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66
E-mail: ir@dermapharm.com

 

 


10.09.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.com
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1129983

 
End of News DGAP News Service

show this